This trial is testing whether the drug abaloparatide can help heal fractures in postmenopausal women and men over 50. The study will last for 3 months, with participants taking either the drug or a placebo. The trial will be extended for 9 months to see if there are any differences between the groups.
1 Primary · 4 Secondary · Reporting Duration: 12 months
78 Total Participants · 2 Treatment Groups
Primary Treatment: abaloparatide prefilled syringe · Has Placebo Group · Phase 2
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: